Angiographic characteristics of definite stent thrombosis: Role of thrombus grade, collaterals, epicardial coronary flow, and myocardial perfusion

Objectives To characterize the prevalence of thrombus burden, collateral vessels to the infarct‐related artery, epicardial coronary artery flow, and myocardial perfusion in patients with angiographically confirmed definite stent thrombosis (ST), and to define their relationship with associated treat...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Catheterization and cardiovascular interventions 2015-01, Vol.85 (1), p.13-22
Hauptverfasser: Reeves, Ryan R., Patel, Mitul, Armstrong, Ehrin J., Sab, Shiv, Waldo, Stephen W., Yeo, Khung-Keong, Shunk, Kendrick A., Low, Reginald I., Rogers, Jason H., Mahmud, Ehtisham
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objectives To characterize the prevalence of thrombus burden, collateral vessels to the infarct‐related artery, epicardial coronary artery flow, and myocardial perfusion in patients with angiographically confirmed definite stent thrombosis (ST), and to define their relationship with associated treatments and outcomes. Background Angiographic characteristics of ST are not well defined. Methods All cases of angiographically determined ST at five academic hospitals from 2005 to 2012 were reviewed. Demographic, procedural, and angiographic characteristics were recorded. In‐hospital and 1‐year follow‐up data were obtained. Results Among 205 cases of angiographic definite ST (60 ± 8 years; 87% male), the majority presented with late/very late ST (69%) and STEMI (66%). High‐risk angiographic findings at presentation included thrombus grade 4–5 (87%), absence of collateral vessels (76%), and reduced initial TIMI 3 flow (90%). Final TIMI 3 flow was achieved in 90% of patients and was associated with greater use of aspiration thrombectomy (60% vs. 25%; P = 0.003), glycoprotein IIb/IIIa inhibitors (80% vs. 30%, P 
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.25519